GlassScriptPhysician profile
Marie S Basa
NPI 1356739767
$6,221.07
in general payments reported to CMS, 2019-2025
34 companies · $808 in 2025
The $808 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,639 · 2022: $1,830 · 2023: $986 · 2024: $957 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,835.84 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $917.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $776.38 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $574.57 | 2021-2025 | |
| Lilly USA, LLC | $489.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $195.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $182.88 | 2021-2024 | |
| Dexcom, INC. | $127.28 | 2023-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $119.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.93 | 2021-2025 | Jardiance |
| Atricure, INC. | $106.74 | 2023 | |
| Amgen INC. | $81.09 | 2024-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $80.76 | 2022-2025 | |
| Abbott Laboratories | $77.84 | 2022-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $53.79 | 2023-2025 | Rexulti, Jynarque |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $47.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.72 | 2022 | |
| Harmony Biosciences LLC | $39.48 | 2024 | |
| Horizon Therapeutics Plc | $38.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.58 | 2024 | Quviviq |
| Getinge USA Sales, LLC | $37.51 | 2025 | Vasoview Hemopro 2 |
| Ascensia Diabetes Care US INC. | $25.67 | 2024 | |
| Exact Sciences Corporation | $24.76 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $23.45 | 2024 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $22.39 | 2021 | |
| Shield Therapeutics INC | $22.15 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $21.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.71 | 2025 | Ultomiris |
| Optos, INC. | $16.52 | 2021 | |
| Eisai INC. | $15.22 | 2021 | |
| Tactile Systems Technology INC | $14.75 | 2021 | |
| Cequr Corporation | $13.99 | 2024 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2025 | Zoryve |
| Astellas Pharma US INC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Basa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.